Smell and Taste Problems in People Using Glucagon-Like Peptide-1 Receptor Agonist Medicines

Patients using GLP-1 receptor agonists have a 48% increased risk of experiencing smell and taste disturbances.

• The study involved 438,474 patients in both the GLP-1 RA group and the control group.
• Patients treated with GLP-1 RAs showed a hazard ratio of 1.48 for overall smell and taste disturbances compared to controls.
• The risk of smell disturbances was particularly high, with a hazard ratio of 1.81.
• Taste disturbances were also more common among GLP-1 RA users, with a hazard ratio of 1.52.
• These associations were consistent over a follow-up period ranging from 3 months to 2 years.

Simplified